Hussman Strategic Advisors Inc. increased its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 40.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 14,700 shares of the medical research company's stock after purchasing an additional 4,200 shares during the period. Amgen comprises about 1.1% of Hussman Strategic Advisors Inc.'s investment portfolio, making the stock its 9th biggest holding. Hussman Strategic Advisors Inc.'s holdings in Amgen were worth $3,831,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pathway Financial Advisers LLC grew its holdings in shares of Amgen by 33,125.4% during the third quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company's stock valued at $1,437,115,000 after buying an additional 4,446,757 shares in the last quarter. International Assets Investment Management LLC boosted its position in Amgen by 6,812.4% during the 3rd quarter. International Assets Investment Management LLC now owns 2,523,387 shares of the medical research company's stock worth $8,130,610,000 after acquiring an additional 2,486,882 shares during the period. Assenagon Asset Management S.A. grew its stake in Amgen by 561.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,539,733 shares of the medical research company's stock valued at $496,117,000 after acquiring an additional 1,306,982 shares in the last quarter. Van ECK Associates Corp increased its holdings in shares of Amgen by 263.8% in the 4th quarter. Van ECK Associates Corp now owns 1,038,593 shares of the medical research company's stock valued at $270,699,000 after purchasing an additional 753,147 shares during the period. Finally, Nordea Investment Management AB lifted its position in shares of Amgen by 40.7% in the fourth quarter. Nordea Investment Management AB now owns 2,338,665 shares of the medical research company's stock worth $609,526,000 after purchasing an additional 676,598 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.
Amgen Price Performance
Shares of Amgen stock traded up $5.08 during trading on Friday, hitting $303.01. 3,260,757 shares of the company's stock traded hands, compared to its average volume of 3,124,757. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The company has a market cap of $162.78 billion, a PE ratio of 40.13, a PEG ratio of 2.55 and a beta of 0.56. The firm's fifty day moving average price is $275.62 and its 200 day moving average price is $300.75.
Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Analysts forecast that Amgen Inc. will post 20.6 earnings per share for the current year.
Amgen Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.14%. Amgen's dividend payout ratio is 126.09%.
Insider Activity at Amgen
In related news, EVP Murdo Gordon sold 8,771 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total value of $2,585,603.09. Following the completion of the transaction, the executive vice president now owns 44,186 shares in the company, valued at $13,025,590.94. The trade was a 16.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 in the last three months. Corporate insiders own 0.69% of the company's stock.
Analyst Ratings Changes
Several research firms have weighed in on AMGN. Piper Sandler upped their price objective on shares of Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Piper Sandler Companies reaffirmed an "overweight" rating and issued a $310.00 price target on shares of Amgen in a research note on Thursday, January 2nd. Bank of America increased their price objective on Amgen from $256.00 to $275.00 and gave the stock an "underperform" rating in a report on Thursday, February 6th. Wolfe Research started coverage on Amgen in a research note on Friday, November 15th. They issued a "peer perform" rating on the stock. Finally, Leerink Partners cut their price target on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $314.09.
Read Our Latest Stock Report on AMGN
About Amgen
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Articles
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
